Most Read Articles
01 Mar 2016
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
01 Mar 2016
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
16 Dec 2018
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.

Risks of acute myocardial infarction, heart failure high in inflammatory bowel disease

24 May 2018

Patients with inflammatory bowel disease (IBD) are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.

A total of 736 IBD patients (339 with Crohn’s disease; 397 with ulcerative colitis) and 1,472 matched controls were followed for a total of 11,398 person-years and 17,880 person-years, respectively, for the development of AMI or heart failure.

On Cox proportional hazards analysis adjusted for traditional cardiovascular disease risk factors, IBD was independently associated with elevated risks of AMI (adjusted hazard ratio [aHR], 2.82; 95 percent CI, 1.98–4.04) and heart failure (aHR, 2.03; 1.36–3.03). The increase in the risk of these cardiovascular disorders was observed in both patients with Crohn’s disease (aHR vs controls, 2.89; 1.65–5.13) and ulcerative colitis (aHR vs controls, 2.70; 1.69–4.35).

When assessed separately, the risk of AMI was elevated in systemic corticosteroid users (aHR vs controls, 5.08; 3.00–8.81) and nonusers (aHR vs controls, 1.79; 1.08–2.98).

On the other hand, the risk of heart failure was significantly high in patients with ulcerative colitis (aHR, 2.06; 1.18–3.65) but not in those with Crohn’s disease, and in systemic corticosteroid users (aHR, 2.51; 1.93–4.57) but not in nonusers.

The present data should prompt close monitoring of IBD patients for the development of cardiovascular disorders, researchers said. Additional studies are needed to investigate whether controlling systemic inflammation could ultimately prevent AMI and heart failure in this population.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2016
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
01 Mar 2016
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
16 Dec 2018
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.